Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.56 |
| ▸ | BRD4 | O60885 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | BRD2 | P25440 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20291227 | 0.90 | HCRTR1 (0.55) | HCRTR1HCRTR2BRD4BRD2ALDH1A1 | |
| SCHEMBL23787099 | 0.90 | BRD4 (0.60) | HCRTR1HCRTR2BRD4MAPTTHRB | |
| SCHEMBL20291072 | 0.85 | BRD4 (0.73) | HCRTR1HCRTR2BRD4SMN1; SMN2BRD2 | |
| SCHEMBL20291205 | 0.84 | HCRTR1 (0.71) | HCRTR1HCRTR2BRD4MAPTSMN1; SMN2 | |
| SCHEMBL30599698 | 0.84 | HCRTR1 (0.71) | HCRTR1HCRTR2BRD4MAPTSMN1; SMN2 | |
| SCHEMBL20291390 | 0.82 | ALDH1A1 (0.65) | HCRTR1HCRTR2BRD4MAPTTHRB | |
| SCHEMBL20291277 | 0.82 | BRD4 (0.57) | HCRTR1HCRTR2BRD4SMN1; SMN2BRD2 | |
| SCHEMBL20291414 | 0.81 | BRD4 (0.66) | HCRTR1HCRTR2BRD4MAPTSMN1; SMN2 | |
| SCHEMBL20291408 | 0.81 | ALDH1A1 (0.58) | HCRTR1HCRTR2BRD4SMN1; SMN2BRD2 | |
| SCHEMBL23787086 | 0.80 | BRD4 (0.60) | HCRTR1HCRTR2BRD4MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554503-B1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | UNIV TEXAS (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3554503-B1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | UNIV TEXAS (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11117865-B2 | Inhibitors of bromodomain-containing protein 4 (BRD4) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2018112037-A1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | ZHOU JIA (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117865-B2 | Inhibitors of bromodomain-containing protein 4 (BRD4) | BRD4, NFKBIA, NFRKB | HCRTR1 2844/4885HCRTR2 3198/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.